Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.

British Journal of Cancer
Sherko KümmelDirk Elling

Abstract

We evaluated the survival benefit, safety, feasibility, and tolerability of dose-dense (DD) adjuvant chemotherapy with epirubicin and paclitaxel for women with node-positive primary breast cancer. Randomised patients (n=216) received DD or conventional-schedule (CS) chemotherapy. Dose-dense regimen patients (n=108) received epirubicin 90 mg m-2 plus paclitaxel 175 mg m-2 in four 14-day cycles, then cyclophosphamide 600 mg m-2, methotrexate 40 mg m-2, and fluorouracil 600 mg m-2 (CMF 600/40/600) in three 14-day cycles, plus filgrastim 5 microg kg day-1 as growth support in every cycle. Conventional-schedule regimen patients (n=108) received epirubicin 90 mg m-2 plus cyclophosphamide 600 mg m-2 in four 21-day cycles, then CMF 600/40/600 in three 21-day cycles, plus filgrastim if required. After a median follow-up of 38.4 months, 71 patients (33%) relapsed or died: DD, 33 patients (15 deaths); CS, 38 patients (22 deaths). Dose dense showed a trend for improved disease-free survival (DFS) and overall survival (OS). Four-year rates of DFS and OS were 64 and 85% for DD, and 58 and 75% for CS. All seven cycles were administered to 208 patients (96%). Rates of cycle delay, discontinuation, dose reduction, and adverse events were simila...Continue Reading

References

Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
May 5, 1994·The New England Journal of Medicine·W C WoodC R Ferree
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Bonadonna
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology
Dec 18, 2001·Cancer·B K LinkUNKNOWN Oncology Practice Pattern Study Working Group
Jan 16, 2002·Breast Cancer : the Journal of the Japanese Breast Cancer Society·S Glück
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
Apr 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jacques BonneterreIsabelle Chapelle-Marcillac
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators

❮ Previous
Next ❯

Citations

Nov 26, 2010·Journal of the National Cancer Institute·Luisa BonillaSalomon M Stemmer
Nov 26, 2010·Journal of the National Cancer Institute·Pia Herbolsheimer, Sandra M Swain
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
Aug 2, 2017·American Journal of Clinical Oncology·Hiroko MachidaKoji Matsuo
Jan 16, 2007·Current Opinion in Obstetrics & Gynecology·Sherko KümmelPeter Schmid
Sep 3, 2008·Nature Clinical Practice. Oncology·Linda Vahdat
Jul 22, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jordi GinésMiguel A Casado
Sep 3, 2019·The Cochrane Database of Systematic Reviews·Melina L WillsonNicholas Wilcken
Oct 19, 2007·The Cochrane Database of Systematic Reviews·T FergusonA K Nowak
Feb 15, 2013·Expert Review of Anticancer Therapy·Markus Joerger, Beat Thürlimann
Jan 5, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Orit FreedmanMark Clemons
Mar 1, 2014·Oncology Nursing Forum·Ellen Catuiza Mullen
Feb 26, 2019·Breast Care·Fernando Kude de Almeida, Daniela Dornelles Rosa
May 16, 2012·The Breast Journal·Soley Bayraktar, Banu Arun
Nov 26, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

© 2022 Meta ULC. All rights reserved